Amgen's Corlanor (ivabradine) Receives FDA's Approval to Reduce Risk of Hospitalization for Worsening Heart Failure in Patients with Chronic Heart Failure
Shots:
- The approval is based on P-III SHIFT study trial assessing Corlanor vs PBO +SoC in 6500+ patients with reduced left ventricular function (LVEF ≤35%) and heart rate ≥70 bpm- hospitalization for heart failure within the past 12 months
- The P-III study resulted in reduction in risk of primary composite endpoint of hospitalization or cardiovascular death for worsening heart failure- 18% relative risk reduction (RRR) and 4.2% absolute risk reduction (ARR)- no effect on motality- 2.6% RRR (4.7% ARR)
- Corlanor (ivabradine) is an oral drug with recommended dose 5mg (bid) that blocks hyperpolarization-activated cyclic nucleotide-gated (HCN) channel responsible for the cardiac pacemaker- which regulates heart rate
Click here to read full press release/ article | Ref: Amgen | Image: Signbox
Tags
This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com